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Abstract: Diagnosis and classification of aggressive mature B-cell lymphoma with atypical morphology remains a
challenge. To identify factors that may contribute to the atypical morphology, we selected eight such cases and
evaluated their morphologic, immunophenotypic and cytogenetic features and clinical outcomes. The neoplastic
cells showed a diffuse monotonous infiltrating pattern with a spectrum of morphology including: 1) L1
lymphoblastic; 2) centroblastic; 3) immunoblastic; and 4) mixed centroblastic and immunoblastic. The lymphoma
cells in most cases were positive for CD10 and/or BCL6, and showed BCL2 expression. 6 of 8 cases showed CMYC rearrangements, and interestingly, all 6 cases demonstrated a proliferation index of <90%. 3 of the 6 cases
also demonstrated t(14;18). Clinical follow-up indicated that aggressive mature B-cell lymphoma may benefit from
more intensified chemotherapeutic regimens used for BL. Our study suggests that aggressive mature B-cell
lymphoma with atypical morphology may be another “grey zone lymphoma” lying in the spectrum between Burkitt
lymphoma and diffuse large B-cell lymphoma.
Key Words: Aggressive mature B-cell lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, grey zone
lymphoma, C-MYC rearrangement

Introduction
Classical
Burkitt
lymphoma
(BL)
is
characterized morphologically by a diffuse
proliferation of monotonous medium-sized
lymphoma cells with round nuclei, small
nucleoli and high proliferative as well as
apoptotic indices. Interspersed in the sea of
round "blue" cell tumor are Tingible-body
macrophages with abundant clear cytoplasm
and apoptotic bodies, imparting a "starry-sky"
pattern of the neoplasm at low magnification
[1]. BL is invariably associated with C-MYC
over-expression as a result of C-MYC gene
rearrangements. In contrast, diffuse large Bcell
lymphoma
(DLBCL)
includes
a
heterogeneous group of intermediate to highgrade mature B cell neoplasms. The
lymphoma cells are usually larger and show
more variation in cell size and the amount of
cytoplasm with vesicular chromatin and more
prominent nucleoli [2].
Because of the drastic difference in molecular
mechanism, treatment regimens and clinical

outcomes, it is imperative to correctly
diagnose and classify BL or DBLCL. With the
help of immunophenotyping and cytogenetics,
it is usually possible to differentiate classical
BL from typical DLBCL. Both lymphomas are
positive for all the mature B-cell markers, and
sometimes CD10 and BCL6. Classical BL has a
nearly 100% proliferation index and is always
negative for BCL2 [3]. On the other hand,
DLBCL in general shows a <90% proliferation
index and is frequently positive for BCL2 [4]. In
addition, C-MYC gene rearrangements are
present in virtually all classical BLs, but only in
a minority of DLBCLs.
Problem arises when morphology of the
lymphoma cells is not characteristic of either
BL or DLBCL, herein referred to as aggressive
mature B-cell lymphoma with atypical
morphology. On one hand, the lymphoma cells
are monotonous resembling classical BL or
lymphoblastic lymphoma; however, they
usually have more abundant cytoplasm,
irregular nuclei, and sometimes more
prominent nucleoli, consistent with the
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cytological features of DLBCL. On the other
hand, these cells do not show the variations in
size and shape usually seen in typical DLBCL.
Recognizing this problem, a provisional entity
of “atypical Burkitt/Burkitt-like lymphoma” was
introduced to define some of these cases with:
1) a characteristic BL immunophenotype; 2) a
nearly 100% proliferation index; and 3)
consistent presence of C-MYC translocations
in the most recent WHO lymphoma
classification [2]. Cases that do not fulfill all
three criteria are currently considered to be
DLBCL. However, more recent molecular
evidence indicates that these criteria do not
completely differentiate BL from DLBCL, and a
reproducible distinction between BL and
DLBCL is not always possible [5].
In this small series, we present 8 cases of
aggressive mature B-cell lymphoma with
atypical morphology. Although these cases
may fall into the category of DLBCL by the
current WHO classification, due to their
atypical features and high clinical suspicion for
BL, these cases were extensively analyzed by
immunohistochemistry and fluorescence in
situ hybridization (FISH). The results indicate
that these cases may represent another “grey
zone lymphoma” lying in the spectrum
between BL and DLBCL.
Materials and Methods
Selection of Cases
All cases in this study were selected from the
archives of the Department of Pathology,
Barnes-Jewish Hospital and the Laboratories
of Pathology, University of Maryland Medical
Center from July 2004 to June 2006. This
selection was based on the clinical suspicion
of BL, atypical morphology and available
cytogenetic data. None of the patients had a
documented history of HIV infection. The
Institutional Review Boards from both
institutions have approved the study.
Tissue Sources
Cervical lymph node or bone marrow biopsies
were performed on most patients, with one
half of the specimens fixed in 10%
formaldehyde and the other half submitted for
immunophenotypic analysis. Tissue sections
were prepared from the formalin-fixed and
paraffin-embedded biopsies using standard
techniques. The sections were stained with
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routine
hematoxylin-eosin
(H&E).
The
morphology was reviewed independently by
two hematopathologists. When there was
discrepancy, FISH studies using the C-MYC
break-apart and IGH/BCL2 dual fusion probe
sets were performed. A consensus diagnosis
was reached based on morphology,
immunophenotype and the status of C-MYC
rearrangement in the tumor with clinical
correlation.
Immunohistochemistry
Immunohistochemical stains were performed
using a Biotek Techmate 1000 autostainer
(Ventana Medical Systems, Tucson, AZ)
according to the manufacturer's protocol.
Mouse anti-human CD3, CD5, CD20, CD79a,
BCL2, BCL6, Ki-67, MUM-1 and TdT (DAKO
Corporation, Carpenteria, CA) were used as the
primary antibodies. Horseradish peroxidaselabeled
rabbit
anti-mouse
polyclonal
antibodies were employed to convert the
chromogen 3, 3’-diaminobenzidine tetrahydrochloride substrate. All stains were performed
with appropriate positive and negative
controls. The proliferation indices were
expressed as percentages and calculated
using the formula (number of Ki-67+
cells/number of CD20+ cells) x 100. The
number of CD79a+ cells was used in the
formula for the CD20-negative case (patient
3). Background T-cells were excluded from
assessment of the proliferation indices.
Flow Cytometric Immunophenotyping
Immunophenotyping was performed using the
FC500 four-color flow cytometer (BeckmanCoulter, Miami, FL) according to the standard
protocol (Becton-Dickinson, San Jose, CA).
Directly conjugated monoclonal antibodies
(Beckman-Coulter, Miami, FL) to the following
antigens were used for this analysis: CD3
(UCHT-1),
CD4
(SFC112T4D11),
CD5
(SFC124T6G12),
CD7
(8H8.1),
CD8
(SFC121Thy2D3), CD10 (J5), CD19 (PC5),
CD20 (B9E9), CD23 (HD50), CD45 (J.33),
CD79a (HM47), FMC7 (FMC7), HLA-DR (Immu357)
and
terminal
deoxynucleotidyl
transferase
(TdT)
(HT1+HT4+HT8+HT9).
Directly conjugated monoclonal antibodies
against CD2 (55.2) were obtained from
Becton-Dickinson, San Jose, CA. Polyclonal
rabbit anti-human immunoglobulin light chains
were
obtained
from
DakoCytomation,
Carpenteria, CA. All antibodies were
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conjugated with fluorescein isothiocyanate
(FITC), phycoerythrin (PE), peridinin chlorophyll
protein (PCP) or allophycocyanin (APC). The
flow cytometric data was analyzed using
CellQuest software (Becton-Dickinson, San
Jose, CA).
Fluorescence In Situ Hybridization (FISH)
Analysis
Dual-color FISH was performed either on
lymph nodes or on cells from bone marrow as
previously described [6]. Commercially
available dual color break-apart C-MYC and
dual fusion IGH/BCL2 probe sets were used
following the manufacturer’s instructions
(www.Vysis.com). The LSI MYC Dual Color,
Break Apart Rearrangement Probe is a mixture
of two probes that hybridize to opposite sides
of the C-MYC gene (The SpectrumOrangeTM
labeled 5' LSI MYC probe begins upstream of
the 5' end of C-MYC and extends 260 kb
toward the centromere. The SpectrumGreenTM
3' LSI MYC probe starts about 1 Mb 3' of CMYC and extends toward the telomere for
about 400 kb) (www.Vysis.com). This probe set
can detect the C-MYC rearrangements involved
in
almost
all
the
breakpoints
for
t(8;14)(q24;q32),
t(8;22)(q24;q11)
and
t(2;8)(p11;q24). For FISH on lymph nodes, thin
sections (5-6 μm) from formalin-fixed paraffinembedded block were mounted on poly-Llysine–coated slides. After deparaffinization,
the sections were subjected to “antigen
retrieval” using “steam cooking” in citrate
buffer for 20 minutes, followed by re-hydration.
After pepsin digestion at 37ºC for 30 minutes
and a subsequent wash in 2 x SSC, the slides
were allowed to air dry and followed by FISH
analysis. After the hybridization, nuclei were
counterstained with 4′6-diamidino-2-phenylindole·2HCl (0.5 μL/mL), and the sections were
viewed under an Olympus BX60 fluorescent
microscope with appropriate filters (Olympus,
Melville, NY). Hybridizations were digitally
photo-graphed using a high-resolution COHU
CCD black-and white camera, with a Z-stack
motor programmed to capture images at
sequential 4′6-diamidino-2-phenylindole·2HCl
(1 level), fluorescein isothiocyanate (5 levels),
and rhodamine (5 levels) filter settings.
Reconstruction into a single superimposed
image with blue, green, and red pseudocolors
was accomplished using the CytoVision
workstation software (Applied Imaging, Santa
Clara, CA).
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Results
There were four in-house (patients 1, 3, 4 and
7) cases and four outside consultation
(patients 2, 5, 6 and 8) cases in this study.
There was equal number of male and female
patients. Their age ranged from 19 to 71 years
with a median age of 63. The patient
information, treatment regimens and clinical
follow-up are summarized in Table 1.
All lymphomas were composed of a
monotonous population of neoplastic cells
resembling BL. However, they demonstrated
various atypical morphologic features often
seen in DLBCL. These included L1
lymphoblastic, centroblastic, immunoblastic,
and mixed centroblastic and immunoblastic
morphology (Figure 1). Unlike typical DLBCL,
these cases showed less variation in size and
shape of the neoplastic cells. Some of the
neoplastic cells have abundant basophilic
cytoplasm,
cytoplasmic
vacuoles
and
prominent nucleoli (Figure 2).
As summarized in Table 2, the lymphoma cells
expressed CD20 in all but one cases. The
lymphoma cells in the one CD20-negative case
were positive for CD79a and expressed
surface immunoglobulin light chain. BCL2 was
positive in 5 of 6 cases that had C-MYC
rearrangements. The lymphoma cells were
either positive for both CD10 and BCL6 (3/8),
or at least one of these two markers (4/8),
indicating their germinal center origin.
Interestingly, however, MUM-1 was positive in
all 4 cases analyzed and in 2 of the 4 cases
the lymphoma cells were positive for CD10.
The lymphoma cells in 6 of 8 cases showed a
proliferation
index.
Extensive
<95%
immunohisto-chemical studies were not
performed on case 5 due to the lack of
additional tissue.
With the break-apart C-MYC probe, we
identified
the
presence
of
C-MYC
rearrangements in all 6 cases with <90%
proliferation indices (Figure 3 and Table 2).
Conversely, no C-MYC rearrangement was
detected in the remaining 2 cases with >95%
proliferation
rates.
Although
C-MYC
rearrangement is characteristic of BL, it has
also been identified in rare cases of DLBCL [4,
7]. In contrast, t(14;18) was present in about
30% of DLBCL, but was never detected in
classical BL [8]. To further characterize these
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Table 1 Clinical information of the patients
Case #

Age/Sex

Diagnosis

Treatment

Clinical outcome

1

52/M

Large B-cell lymphoma, stage IA; Status post failed
autotransplant; Recurrence in CNS

High dose methotrexate, ARA-C, Rituxan;
intrathecal methotrexate and ARA-C

Alive (8 years) with refractory
disease; in hospice

2

67/F

High-grade large B-cell lymphoma

Combined chemotherapy and radiation therapy

Alive (22 months) with no
evidence of disease

3

71/M

Low-grade B-cell lymphoma for 8 years; High-grade Bcell lymphoma

Salvage chemotherapy with CHOP

Died of refractory disease (8
months)

4

64/F

Large B-cell lymphoma

CHOP+Rituxan, subsequently changed to CALGB
trial with intrathecal therapy

Alive (12 months) with no
evidence of disease

5

19/M

Diffuse large B-cell lymphoma, stage IV

Reduction with vincristine, prednisone and
cyclophosphamide for 7 days; Induction with
vincristine, prednisone, methotrexate,
cyclophosphamide and doxorubicin for 7 days;
Consolidation with methotrexate, hydrocortisone,
ARA-C and prednisone

Alive (24 months) with no
evidence of disease

6

71/M

High-grade B-cell lymphoma

CHOP+Rituxan x 4 cycles

Alive (3 months)

7

62/F

Atypical Burkitt lymphoma

High dose chemotherapy involving methotrexate
with leukovorin rescue

Died primarily of renal
insufficiency 4 months after
diagnosis

8

36/F

Diffuse large B-cell lymphoma

CHOP+Rituxan x 6 cycles

Alive (18 months) with no
evidence of disease
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Table 2 Characteristics of aggressive mature B-cell lymphomas with atypical morphology
Immunophenotype
Case #

CD20

CD79a

CD10

BCL2

BCL6

MUM-1

KI-67

C-MYC

IHG/BCL2

Others

1

+

NTa

+

+

+

+

~50%

+

+

Polysomy 8

2

+

+

-

+

+

NT

~90%

+

NT

None

3

-

+b

+

+

-

+

~70%

+

+

None

4

+

-

-

+

+

+

~90%

+

-

Polysomy 8

5

+

NT

NT

NT

NT

NT

~50%

+

-

None

6

+

NT

+

+

+

NT

~90%

+

+

None

7

+

+

+

+

+

NT

~100%

-

NT

None

8

+

NT

-

-

+

+

~95%

-

-

None

aNT:
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Cytogenetics/FISH results

Not tested; bby flow cytometry
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Figure 1 Morphologic variations in aggressive mature B-cell lymphomas with atypical morphology (H&E, x 400
magnification). A. L1 lymphoblastic morphology: a monotonous population of medium-sized neoplastic cells with
scant cytoplasm, round nuclei and small nucleoli (from patient 3); B. Centroblastic morphology: large cells with
abundant cytoplasm, vesicular nuclei and small nucleoli; C. Immunoblastic: large cells with abundant cytoplasm
and single centrally located prominent nucleolus; D. Centroblastic and immunoblastic morphology: with features
of (B) and (C).

lymphomas, FISH studies were performed on
all cases to evaluate the presence of
IGH/BCL2 fusion gene associated with
t(14;18). The results showed that IGH/BCL2
was present in 3 of the 6 cases with C-MYC
rearrangements and <90% proliferation
indices (Table 2). However, t(14;18) was not
detected in the remaining 2 cases with >95%
proliferation indices and absent C-MYC
rearrangements. As controls, FISH was also
performed in two additional cases of classical
BL and two additional cases of typical DLBCL.
None of these cases harbored the
t(14;18)(data not shown).
The therapeutic regimens were modified
accordingly based on the FISH results. Two
cases (cases 1 and 4) with C-MYC
rearrangements
responded
poorly
to
Rituximab
(R),
Cyclophosphamide
(C),
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Adriamycin (H), Vincristine (O) and Prednisone
(P) (R-CHOP) previously, but later responded
favorably to intensified chemotherapy (Table
1). After C-MYC rearrangement was identified,
two cases (cases 2 and 5) were treated with
either combined chemotherapy/radiation
therapy or intensified chemotherapy; both are
currently in remission for almost two or over
two years. One patient (case 3) with C-MYC
rearrangement failed salvage CHOP therapy
and died, and another (case 6) was followed
for only 3 months after R-CHOP. C-MYC
rearrangements were not detected in two
patients: one responded well to R-CHOP and
remained disease-free for 18 months (case 8);
the other was treated with high dose
chemotherapy including methotrexate and
died of renal failure 4 months after the
diagnosis (case 7). Although the number of
patients is small, it appears that patients with

Int J Clin Exp Pathol (2008) 1, 65-74

Zhao et al/C-MYC Rearrangements in Aggressive Mature B-Cell Lymphoma

Figure 2 Aggressive mature B-cell lymphoma with
atypical morphology in bone marrow (from patient
6). The bone marrow aspirate showed several large
lymphoid cells with abundant basophilic and
vacuolated cytoplasm, irregular nuclei and multiple
prominent nucleoli (Wright-Giemsa, x 1000
magnification). These cells have sizes similar to the
adjacent promyelocyte and myelocytes.

aggressive mature B-cell lymphoma with
atypical morphology and C-MYC rearrangements have benefited from the intensified
chemotherapeutic regimens for BL rather than
R-CHOP for DLBCL.
Discussion
We retrospectively evaluated 8 cases of
aggressive mature B-cell lymphoma with
atypical morphology during a two-year period
from
two
medical
centers.
C-MYC
rearrangements are frequently found in these
lymphomas (6/8, 75%). In addition, these
lymphomas also frequently harbor t(14;18)
(3/5, 60%) and/or trisomy 8 (2/6, 20%)
genetic abnormalities. The current study
indicates that these genetic abnormalities
might be associated with the atypical
morphology of aggressive B-cell lymphomas.
Interestingly, C-MYC rearrangements are
identified in all 6 cases with <90%
proliferation index, but are not detected in the
remaining 2 cases with >95% proliferation
index, demonstrating a poor correlation
between the proliferation index and C-MYC
rearrangements. Although this series is small,
the results demonstrate the potential pitfall of
using a near 100% proliferation rate as a
surrogate marker for the diagnosis of BL. With
overlapping features of BL and DLBCL, these
aggressive mature B-cell lymphomas with
atypical morphology may be another “grey
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Figure 3 FISH analysis using the c-MYC break-apart
probe set. A. A c-MYC rearrangement is present
(patient 1) as indicated by splitting apart of the
normal red-green fusion signal into one red
(centromeric end of MYC) and green (telomeric end
of MYC) signal (arrows); B. An c-MYC rearrangement
is absent (patient 8) as evidenced by the presence
of normal red-green fusion signals only.

zone lymphoma” lying between BL and DLBCL,
and may require molecular studies to further
define them [5, 9, 10].
How should these cases be classified based
on the current information available? In
addition to the neoplastic cells having a
mature B-cell phenotype, they also express
BCL2 as well as CD10 and/or BCL6, which are
markers for germinal center B cells. Both BL
and some of the DLBCL are believed to
originate from the germinal center B-cells
based on their expression of CD10 and/or
BCL6 [11]. It is also believed that BCL2
expression can only be detected in DLBCL, but
not in BL [2-4]. However, Barth et al recently
compared 7 endemic and 7 sporadic BL cases
[12]. They found that a uniform expression of
CD10 was seen only in endemic BL cases
(7/7), and about half of the sporadic BL cases
(4/7) were negative for CD10. One of the
sporadic BL case also expressed BCL2 (1/7). A
recent study of 220 aggressive mature B-cell
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lymphomas demonstrated that >20% of the
molecular Burkitt lymphomas expressed BCL2
[5]. In our study, most cases were positive for
both BCL2 (6/7) and C-MYC rearrangements
(6/8). Although the majority of our cases are
BCL6-positive (6/7), almost half of our cases
(3/7) are negative for CD10 (see Table 2).
Considering the clinical behavior, the cases
with C-MYC rearrangements (6/8) might have
been atypical sporadic BL in retrospect.
The t(8;14) and its variant chromosomal
translocations are currently the most specific
cytogenetic abnormalities for BL [3]. FISH
analysis is one of the most sensitive
approaches
in
identifying
all
these
translocations in routine formalin-fixed
paraffin-embedded tissue sections. However,
the commonly used MYC/IGH probe can only
detect the fusion in ~80% of the BL [13, 14].
Recently, the break-apart C-MYC probe set
(Vysis) was developed to detect t(8;14) as well
as the variant C-MYC rearrangements t(2;8)
and t(8;22)[15]. We opted to use this probe
set in this study because of its increased
diagnostic sensitivity. Although the C-MYC
partner genes are not identified by this
approach, since IG-MYC is much more
common in aggressive mature B-cell
lymphomas [9], most of the partner genes in
our cases are presumably IG. Since C-MYC
gene may be activated by translocations with
other partner genes [16], our approach may be
able to detect those C-MYC rearrangements as
well. With our approach, we have detected CMYC rearrange-ments in most (75%) of our
cases of morphologically aggressive mature Bcell lymphomas. The findings are clinically
relevant because more and more studies
suggested
that
DLBCL
with
C-MYC
rearrangements might have a clinical course
resembling BL [17, 18].
Half of our cases harbor the t(14;18) in
addition to C-MYC rearrangements, which
created a dilemma in classifying these
lymphomas. Although lymphomas similar to
our cases were lumped together with DLBCLs
and the C-MYC rearrangement was considered
a
secondary
event
reflecting
tumor
progression [19], recent studies suggested
that DLBCLs with both C-MYC rearrangements
and t(14;18) behaved more aggressively
clinically like BL [17, 18]. Therefore, even if
the C-MYC rearrangement is indeed an event
of progression, the emergence of t(8;14) in
addition to the t(14;18) should perhaps justify
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the interpretation of progression to BL [20],
and thus the lymphoma should be managed
like BL. Further studies are needed to
characterize mature B cell lymphomas with
both C-MYC rearrangement and t(14;18) since
their clinical management may be significantly
different from either BL or DLBCL.
To avoid under- or over-treatment of the
patients, it is critical to distinguish BL from
DLBCL when encountering these aggressive
mature B-cell lymphomas with atypical
morphology. Since diagnosis of BL requires
strict criteria (CD10+, BCL6+, close to a 100%
proliferation index and IG-MYC), many cases
that do not meet all these criteria were
diagnosed as DLBCL, and therefore would not
receive
the
benefit
of
intensified
chemotherapy. More recent studies [5, 9, 10]
suggest that some of those DLBCL cases
indeed had the molecular signatures of BL and
over 10% of those molecular BL did not harbor
any detectable C-MYC translocations [4].
In summary, we should recognize this group of
aggressive mature B-cell lymphomas with
atypical morphology and C-MYC rearrangements when determining chemotherapy, since
more and more studies show that they follow a
similar clinical course as BL [17, 18]. Although
molecular profiling may be the eventual
solution [9, 10], it is not yet ready for real-time
diagnosis [21]. Cytogenetic studies may be
routinely performed in all aggressive mature Bcell lymphomas with atypical morphology. With
the increasing number of reported cases [5, 9,
10, 17, 18], “aggressive mature B-cell
lymphomas with atypical morphology” may
emerge as another “grey zone lymphoma”
between BL and DLBCL, and multicenter
collaborative investigation is essential to
further define the clinical, pathological and
molecular signatures of these lymphomas.
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